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Background and aims
Tumor cell vaccines are widely used as a potential thera-
peutic. Different approaches are currently being applied to
kill tumor cell vaccines prior to injection to prevent out-
growth of metastasis at the site of injection. We and others
have previously shown that the mode by which tumor cells
die can have significant effects on anti-tumor specific
immune responses. Here, we have studied how tumor cell
necrosis impairs immune responses and describe a new
strategy to enhance tumor-specific immune responses to
dying tumor cells.
Methods
B78HI wt, B78HI-Ova, CT26, CT26-Ova, EG7 and NT2.5
tumor cells and C57/BL/6, OT-I and FVB/N mice were
used. Tumor cell death was induced by 3 freeze-thaw
cycles in vitro and gamma-irradiation in vivo and in vitro.
T cell responses were analyzed by tetramer staining, in
vivo CTL and intracellular cytokine analysis. Growth of
subcutaneous tumors was monitored 3 times a week.
Gene knockdowns were done by transfection of tumor
cells with corresponding shRNA constructs. Conventional
gel chromatography followed by mass spectrometry was
performed to identify genes of interest.
Results
Freeze thawed (necrotic) tumor cells failed to induce
anti-tumor immune responses. In contrast heating of
necrotic tumor cells prior to injection or loading heated
necrotic lysates onto dendritic cells reversed their non-
immunogenicity and led to the induction of a potent
anti-tumor immune response determined by in vivo
CTL, tetramer staining and IFN-gamma response. Similar
results were observed in a vaccination setting suggesting
that necrotic cells contain a factor inhibiting induction of
T cell responses. In order to identify this factor we set up
an in vitro system to evaluate the effect of tumor necrosis
on cross-priming. We identified two proteins, dipeptidyl
peptidase 3 (DPP3) and thimet oligopeptidase 1 (TOP1)
in necrotic cells, which were able to block the induction
of T cell responses to dying tumor cells in vitro and in
vivo. In contrast knockdown of DPP3 and TOP1 reversed
the non-immunogenicity of necrotic tumor cells and
supported tumor-specific T cell responses to dying
tumor cells in vitro and in vivo in different tumor
models. Finally, TOP1 knockdown increased tumor-
specific immune responses to subcutaneous tumors after
radiation induced tumor cell death.
Conclusion
DPP3 and TOP1 prevent tumor-specific immune
responses to dying tumor cells and represent important
targets to improve anti-tumor immunity to dying tumor
cells.
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